1. Home
  2. MBINM vs IMNM Comparison

MBINM vs IMNM Comparison

Compare MBINM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Merchants Bancorp

MBINM

Merchants Bancorp

HOLD

Current Price

$25.68

Market Cap

0.0

Sector

Finance

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$26.12

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBINM
IMNM
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
2.5B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
MBINM
IMNM
Price
$25.68
$26.12
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$32.80
AVG Volume (30 Days)
5.5K
956.7K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.40
EPS
2.73
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,127.34
P/E Ratio
$9.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.00
$8.93
52 Week High
$25.96
$30.06

Technical Indicators

Market Signals
Indicator
MBINM
IMNM
Relative Strength Index (RSI) 56.62 47.75
Support Level $25.46 $19.28
Resistance Level $25.71 $27.14
Average True Range (ATR) 0.09 1.10
MACD 0.00 -0.41
Stochastic Oscillator 69.70 9.58

Price Performance

Historical Comparison
MBINM
IMNM

About MBINM Merchants Bancorp

Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: